Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Inhibrx Biosciences, Inc
University of Virginia
University of Pittsburgh
Cancer Research UK
Revolution Medicines, Inc.
Pfizer
Advaxis, Inc.
Revolution Medicines, Inc.
Seagen Inc.
Revolution Medicines, Inc.
MultiVir, Inc.